NRG receives £2.68m funding boost for neurodegenerative disorders
NRG Therapeutics announces multi-million Innovate UK Award to develop treatments for Parkinson’s and motor neurone disease - News - PharmaTimes
Stay updated with breaking news from Arthur Roach. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
NRG Therapeutics announces multi-million Innovate UK Award to develop treatments for Parkinson’s and motor neurone disease - News - PharmaTimes
UK neuroscience company NRG Therapeutics Ltd has received an award to fund preclinical development of its novel small molecule disease-modifying medicines for the treatment of Parkinson's disease, motor neuron disease (MND) and other chronic neurodegenerative disorders.
NRG Therapeutics Ltd (“NRG” or “company”), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that it has received a highly competitive Biomedical Catalyst (BMC) award to fund pre-clinical development of its novel small molecule disease-modifying medicines for the treatment of Parkinson's disease, motor neuron disease (MND) and other debilitating chronic neurodegenerative disorders.
/PRNewswire/ -- NRG Therapeutics Ltd ("NRG" or "company"), an innovative neuroscience company targeting mitochondrial dysfunction, is pleased to announce that...
In recognition of World Parkinson's Day, we speak to Dr. Arthur Roach, Director of Research at Parkinson’s UK, about the current Parkinson's landscape.